Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Br J Dermatol. 2015 Feb 5;172(3):760–768. doi: 10.1111/bjd.13350

B (CD19+) cell subpopulations in subjects treated with infliximab(A) and placebo (B). No significant difference in B cell subpopulations between the study groups was seen at week 0. An increase in proportion of transitional (IgD+/CD38++/CD27−) cells was noted in the infliximab treated subjects at week 26.

B (CD19+) cell subpopulations in subjects treated with infliximab(A) and placebo (B). No significant difference in B cell subpopulations between the study groups was seen at week 0. An increase in proportion of transitional (IgD+/CD38++/CD27−) cells was noted in the infliximab treated subjects at week 26.